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When the succinate receptor (SUCNR1) is activated in the
afferent arterioles of the glomerulus it increases renin release
and induces hypertension. To study its location in other
nephron segments and its role in kidney function, we
performed immunohistochemical analysis and found that
SUCNR1 is located in the luminal membrane of macula densa
cells of the juxtaglomerular apparatus in close proximity to
renin-producing granular cells, the cortical thick ascending
limb, and cortical and inner medullary collecting duct cells.
In order to study its signaling, SUCNR1 was stably expressed
in Madin-Darby Canine Kidney (MDCK) cells, where it
localized to the apical membrane. Activation of the cells by
succinate caused Gq and Gi-mediated intracellular calcium
mobilization, transient phosphorylation of extracellular
regulated kinase (ERK)1/2 and the release of arachidonic
acid along with prostaglandins E2 and I2. Signaling was
desensitized without receptor internalization but rapidly
resensitized upon succinate removal. Immunohistochemical
evidence of phosphorylated ERK1/2 was found in cortical
collecting duct cells of wild type but not SUCNR1 knockout
streptozotocin-induced diabetic mice, indicating in vivo
relevance. Since urinary succinate concentrations in health
and disease are in the activation range of the SUCNR1,
this receptor can sense succinate in the luminal fluid.
Our study suggests that changes in the luminal succinate
concentration may regulate several aspects of renal function.
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G-protein-coupled receptors (GPCRs) have a major role in
the regulation of many (patho-) physiological processes in
the human body. Their role is to transfer signals from the
extracellular environment to the inside of the cell via effector
proteins and multiple cellular signaling pathways. The
receptor GPR91,1 which is related to the family of P2Y
purinoreceptors, was found to be activated by succinate2 and
was therefore renamed succinate receptor 1 (SUCNR1).
Among other organs, SUCNR1 is highly expressed in the
kidney.2 Importantly, there are strong indications that the
SUCNR1 is involved in hyperglycemia and diabetes-induced
hypertension, because rat and mouse models of hypertension
and metabolic syndrome have increased succinate levels when
compared with healthy control animals,3 and injection of
succinate into normal, but not SUCNR1 knockout mice
induces the production and release of renin and hyperten-
sion.2 Also, SUCNR1-mediated renin release has been linked
to hyperglycemia and diabetes.3,4 Therefore, the SUCNR1
may be an important protein in the kidney-derived onset of
hypertension.
Consistent with its role in renal regulation of volume
balance, immunohistochemistry identified expression of
SUCNR1 near the juxtaglomerular apparatus (JGA), in
particular the vascular endothelial cells of the afferent
arteriole and in the glomerulus. Moreover, stimulation of
the SUCNR1 in vascular endothelial cells leads to the
mobilization of intracellular calcium and production of
nitric oxide and prostaglandin (PG) E2 release, which
contribute to the release of renin from granular cells and
vasodilation of the afferent arteriole.4
Interestingly, however, SUCNR1 mRNA has also been
detected in proximal and distal tubules,2 suggesting an
additional role for SUCNR1 in the renal tubule. To increase
our understanding of the function of SUCNR1 in renal
physiology, we analyzed the expression of SUCNR1 along the
nephron, and found that SUCNR1 is also expressed in the
polarized cells of the thick ascending limb of Henle’s loop
(TAL) and the cortical and inner medullary collecting duct
(CCD and IMCD, respectively). As a model for these cells,
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we subsequently generated SUCNR1-expressing polarized
Madin–Darby Canine Kidney (MDCK) cells and analyzed the
regulation of SUCNR1 and its downstream signaling path-
ways on the (sub)cellular level and in vivo.
RESULTS
Localization of SUCNR1 in the kidney
To assess whether SUCNR1 may have a role in renal tubular
physiology, we set out to determine the cellular and
subcellular localization of SUCNR1 in the kidney. Staining
of rat kidney sections for SUCNR1 with antibody Q-15
followed by confocal laser scanning microscopy (CLSM)
clearly shows that the receptor localizes to the luminal
membrane of cells morphologically resembling cells of the
thick ascending limb (TAL) of Henle’s loop (Figure 1a
and b). No staining was observed after preabsorption of the
antibody with the immunizing peptide (not shown). The
specificity of this localization was confirmed by staining with
a second SUCNR1-specific antibody, H-80 (not shown). In
addition, staining with this antibody reveals expression of
SUCNR1 in glomerular cells (Figure 1c and d), which, as
reported,4 likely represent endothelial cells of the glomerular
capillaries and the afferent arteriole. To assess whether the
localization of SUCNR1 is conserved between species,
labeling of mouse kidneys was carried out. Also here,
SUCNR1 was detected in the luminal membrane of the
cortical TAL (Supplementary Figure S1).
As SUCNR1 activity is involved in the release of renin
from the kidney and considering the complex architecture of
the JGA, we further assessed whether the cells expressing
SUCNR1 also express renin, or are in close proximity to
renin-expressing cells. Co-staining of rat kidney sections
revealed that in the cortex, the tubular cells expressing
SUCNR1 do not express renin themselves and that renin is
only expressed in granular arteriolar cells (Figure 1e–h).
SUCNR1-expressing cells in the TAL are often adjacent to
these renin-expressing cells (Figure 1g and h), suggesting that
SUCNR1 is localized to the macula densa (MD). To examine
this possibility at a subcellular level, immunogold electron
microscopy was carried out. As shown in Figure 2, SUCNR1
was detected in MD cells, both in the apical membrane and in
distinct intracellular vesicles morphologically resembling
endosomes.
As shown in Figure 1i, double immunofluorescence
labeling of rat kidney inner medulla for SUCNR1 and
aquaporin-2 (AQP2), a marker for collecting duct principal
cells, revealed that SUCNR1 localizes to the IMCD. At high
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Figure 1 |Renal localization of the SUCNR1. (a)
Immunofluorescence labeling using a SUCNR1 antibody (Q-15)
identified that SUCNR1 is localized to distinct tubule segments.
(b) Overlay with differential interference contrast (DIC) image
identifies that SUCNR1 is localized to the cortical thick ascending
limb of Henle’s loop (TAL). (c) Immunofluorescence labeling using
an alternative SUCNR1 antibody (H-80) localized SUCNR1 to both
cells within the glomerulus and a region of the TAL associated
with the juxtaglomerular apparatus (JGA). (d) Overlay with DIC
image. (e) Double immunofluorescence labeling of SUCNR1 (Q15)
(green) and renin (red) determined that SUCNR1 does not
colocalize with renin in juxtaglomerular cells. (f) Overlay with DIC
image. (g) Double immunofluorescence labeling of SUCNR1 (Q15)
(green) and renin (red). (h) Overlay with DIC image clearly shows
that SUCNR1 is detected in tubules morphologically resembling
the macula densa. (i) Double immunofluorescence labeling
of renal medulla for SUCNR1 (green) and AQP2 (red) determined
that SUCNR1 localizes to the IMCD. At high magnification
(inset, bottom right), it is clear that the majority of SUCNR1
labeling is associated with the apical plasma membrane domains.
(j) Double immunofluorescence labeling of SUCNR1 (green) and
AQP2 (red) in the cortex, where SUCNR1 is very weakly expressed
in AQP2-containing tubules. (k) In the IMCD, SUCNR1 (green) does
not colocalize with the basolateral membrane marker AE2 (red).
(l) In the IMCD, SUCNR1 (green) can be observed in renin-expressing
cells (red). A, arteriole; AQP-2, aquaporin-2; G, glomerulus;
IMCD, inner medullary collecting duct; MD, macula densa;
P, proximal tubule; T, thick ascending limb; SUCNR1, succinate
receptor.
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magnification, it is clear that the majority of SUCNR1
labeling is associated with the apical plasma membrane
domains (inset, bottom right). The same double labeling
performed on the renal cortex (Figure 1j) shows that
SUCNR1 is weakly expressed in AQP2-containing cells,
indicating that the receptor is also expressed in principal
cells of the cortical collecting duct (CCD). No SUCNR1
staining was found in CCD-intercalated cells. In the IMCD,
SUCNR1 also localizes to the apical membrane, as it does not
colocalize with the basolateral membrane marker anion
exchanger (AE)2 (Figure 1k, inset, bottom right and Figure
S2A), which is especially clear in the later portions of the
IMCD (Figure S2B). Moreover, as shown in Figure 1l, IMCD
cells expressing SUCNR1 also express renin. Finally, cells of
the thin descending limb show weak labeling for SUCNR1
(Figure S2B).
Taken together, these data indicate that the SUCNR1 is,
besides endothelial cells of the glomerular vasculature, also
expressed in the luminal membrane of tubular cells from
different renal segments where it may be a sensor for
succinate in the pro-urine.
Localization of SUCNR1 in MDCK cells
Since TAL cells and principal cells of the CCD and IMCD are
polarized, they may have alternative SUCNR1 localization,
trafficking, and signaling properties compared with non-
polarized, for example, endothelial cells.5 Therefore, we
employed Madin–Darby Canine Kidney (MDCK) cells as a
model to study SUCNR1 localization, signaling and regula-
tion. MDCK cells were stably transfected with expression
constructs encoding C-terminally eYFP or c-myc-tagged
SUCNR1 and individual clones were isolated. N-terminal
epitope tags could not be used, because these affected the
localization of SUCNR1 (not shown).
Based on bioinformatical analysis, the SUCNR1 consists of
seven transmembrane domains, which is characteristic for
GPCRs, and has two putative N-glycosylation sites:
one at Asn4 in the N terminus and one at Asn164 in the
second extracellular loop (Figure 3a). CLSM analysis of
MDCK–SUCNR1–eYFP cells revealed a clear expression in the
apical domain of the cells, as it showed overlap with staining
of apically applied wheat-germ agglutinin, and no colocaliza-
tion with the basolateral plasma membrane marker E-
Cadherin (Figure 3b). The localization of SUCNR1 in MDCK
cells is thus similar to what is observed in TAL and CD
principal cells in vivo (Figure 1), indicating that the MDCK
cell is a proper model for MD and principal cells, and that the
C-terminal tag does not interfere with trafficking of the
receptor.
Western blot analysis of SUCNR1–eYFP cells with GFP
antibodies showed a strong signal of approximately
90–100 kDa and a weaker doublet of bands of approx.
60 kDa (Figure 3c). The upper band of this doublet was
absent following digestion with both PNGaseF and EndoH,
suggesting that the lower and upper band represent the
unglycosylated and the high-mannose glycosylated immature
forms of the receptor, respectively. Upon digestion of the
protein mix with PNGaseF, but not endoH, the 90–100 kDa
band completely disappeared into the 60 kDa signal (Figure
3c). This indicates that SUCNR1 is only glycosylated at Asn
(no O-glycosylation) and that the 90–100 kDa band is the
N-linked complex-glycosylated form of the receptor. To-
gether, these observations reveal that SUCNR1 is expressed as
a mature and properly folded receptor when expressed in
MDCK cells.
SUCNR1 signaling in MDCK cells
To determine the signaling characteristics of the SUCNR1 in
polarized cells, we first assessed whether this receptor could
be activated selectively by succinate. As shown in Figure 4a,
administration of the Emax concentration of 200 mmol/l Suc
2
to untransfected MDCK cells did not induce phosphorylation
of extracellular regulated kinase (ERK1/2), whereas these cells
showed a robust signal to addition of serum (Figure 4a). In
contrast, stimulation of MDCK–SUCNR1 cells with succinate
for 5min resulted in increased phosphorylation of ERK1/2
(Figure 4a), whereas they remained unresponsive to admin-
istration of a related compound from the Krebs’ cycle,
a-ketoglutarate (aKG).
Activation of the ERK1/2 pathway by GPCRs can be G-
protein-mediated, which is a rapid and transient process
(o10min), or it can be mediated via b-arrestins, resulting in
a slower and more sustained phosphorylation of ERK1/2.6,7
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Figure 2 | Immunoelectron microscopy of SUCNR1 in rat
kidney. (a) Overview of the macula densa (MD) region of the thick
ascending limb. (b) In the MD cells immunogold labeling of
SUCNR1 (H80) is observed intracellularly (arrowheads) and in the
apical plasma membrane domains (inset, arrows). (c) Using an
alternative SUCNR1 antibody (Q15), a similar pattern of labeling is
observed, with gold particles in direct contact with the plasma
membrane (inset). (d) In some MD cells, very few gold particles are
observed in the plasma membrane. In these cells, labeling of
distinct vesicles morphologically resembling endosomes (*) are
apparent. apm, apical plasma membrane; EM, extraglomerular
mesangium, lm, lateral membrane; MD, macula densa;
PT, proximal tubule.
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As shown in Figure 4b, SUCNR1 activation induced transient
ERK1/2 phosphorylation, which was at its maximum at 2min
after addition of ligand and remained significantly increased
compared with the control at t¼ 5 and 10min (Po0.05;
Student’s t-test), suggesting that ERK1/2 activation by these
receptors is G-protein-mediated.
To further investigate receptor signaling, we employed
FURA-2 measurements to assess receptor-induced intracel-
lular calcium mobilization. SUCNR1-specific activation by
succinate dose-dependently increased calcium mobilization
with a half-maximum potency (EC50) of 23.1±12.8 mmol/l
(Figure 4c). To assess which G proteins were involved in the
SUCNR1-mediated calcium mobilization, we pre-incubated
the cells with YM254890, an inhibitor of Gq/11, or pertussis
toxin (PTX), an inhibitor of Gi/o. Inhibition of Gi resulted
in a decrease in the maximum efficacy (Emax), but did
not significantly affect the potency of the signal
(EC50¼ 22.1±14.1 mmol/l) (Figure 4c). Blockade of the
Gq/11 pathway also resulted in a marked reduction of the
maximal efficacy and also resulted in a shift of the EC50 to
67.4±14.7 mmol/l. Combined application of the blockers
resulted in complete absence of calcium mobilization in
response to succinate (Figure 4c). These data suggest that the
SUCNR1 uses both the Gq/11 and Gi/o pathways to increase
intracellular calcium and induce ERK1/2 phosphorylation.
SUCNR1 activation triggers the release of arachidonic acid
and the production of prostaglandins
As intracellular calcium mobilization and ERK1/2 phosphor-
ylation can induce the release of arachidonic acid (AA),8 a
precursor of prostaglandins, we tested whether activation of
SUCNR1 was able to induce the release of AA from MDCK
cells. As shown in Figure 5a, untransfected control cells did
not respond to 200 mmol/l Suc, but released [3H]AA could be
measured after stimulation of endogenous purinoreceptors
with 100 mmol/l ATP or induction of a calcium flux with
1 mmol/l of the calcium ionophore ionomycin. In SUCNR1
cells, however, stimulation with succinate triggered the
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Figure 3 | Subcellular localization and glycosylation state of SUCNR1 in MDCK cells. (a) Topology of the SUCNR1: The structure of
GPCRs is composed of seven transmembrane domains, indicated in roman numbers. Using bioinformatic tools on the amino acid sequences
of SUCNR1, we predicted the topology of the receptor and the location of its potential N-glycosylation sites. (b) Subcellular localization
of the SUCNR1: MDCK–SUCNR1–eYFP cells were seeded on filters, grown to confluence, and labeled with the plasma membrane markers
E-Cadherin (basolateral membrane) or wheat-germ agglutinin (WGA; apical membrane), followed by CLSM analysis. Shown are representative
XY scans and a corresponding cross-section. (c) Glycosylation state of the SUCNR1: MDCK–SUCNR1–eYFP cells were lysed, left untreated
(control), or digested with endoH or PNGaseF (indicated). Samples were analyzed by SDS-PAGE and subjected to immunoblotting using
a sheep-anti-GFP antiserum. CLSM, confocal laser scanning microscopy; GFP, green fluorescent protein; GPCR, G-protein-coupled receptors;
MDCK, Madin–Darby Canine Kidney; eYFP, enhanced yellow fluorescent protein; SUCNR1, succinate receptor.
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release of [3H]AA 2.61±0.09 fold over basal levels. This
release was not significantly different (P40.05; one-way
ANOVA) from the [3H]AA release measured upon ATP or
ionomycin treatment of the SUCNR1 cells.
Next, we determined the identity of the prostaglandins
released by the SUCNR1 cells (Figure 5b). Supernatant
collected from unstimulated SUCNR1 cells contained
prostaglandin (PG)E2, 6-keto-PGF1a (a stable metabolite
from PGI2) and PGF2a. Stimulation with 200 mmol/l
succinate significantly (Po0.05) increased PGE2 in both
the apical and basolateral medium, whereas 6-keto-PGF1a/
PGI2 was only increased in the apical medium (Figure 5b). In
these studies, PFG2a levels remained unaltered (not shown),
whereas thromboxane (Tx)B2 (a stable metabolite from
TxA2) was not detected in the supernatant under any of the
conditions above. These data indicate that stimulation of
SUCNR1 in polarized cells increases the release of PGE2 to
both sides and of PGI2 to only the luminal side.
Desensitization and internalization of the SUCNR1
To prevent continuous signaling, many GPCRs undergo
desensitization and/or internalization shortly after agonist
stimulation. Calcium mobilization measurements showed
that pre-treatment of MDCK–SUCNR1–eYFP cells with
succinate for 15min markedly decreased the Emax value
(88.6±5.3% reduced) and increased the EC50 value (from
26.3 mmol/l for control to 88.9 mmol/l; Figure 6a), which
indicated that the SUCNR1 is indeed desensitized. Following
desensitization, receptors may either be resensitized, or they
can be downregulated. After removal of the ligand, two
washes and only a 15min resensitization period at 371C, the
Emax and EC50 returned to control values (Student’s t-test;
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Figure 4 | ERK1/2 and calcium signaling by the SUCNR1. (a) Ligand specificity of SUCNR1 signaling: Untransfected MDCK cells or
SUCNR1–eYFP cells were grown to confluence and starved overnight and for a subsequent period of 2 h. Next, cells were incubated with
vehicle (control), 200mmol/l succinate (Suc) or aKG (indicated) for 5min at 371C, followed by termination of the reaction on ice. Subsequently,
cells were lysed and analyzed by SDS-PAGE, followed by immunoblotting using anti-total ERK1/2 or anti-phospho-ERK1/2 antibodies. Signals
were quantified using densitometry and are represented as fold increase over control (n¼ 3). (b) Time-dependent ERK1/2 phosphorylation:
MDCK–SUCNR1–eYFP cells were grown and starved as in a and subsequently incubated with 200 mmol/l succinate for the indicated times.
Next, cells were cooled on ice and cell lysates analyzed and quantified as described under a (n¼ 3). (c) Calcium signaling and G-protein
coupling of the SUCNR1: MDCK–SUCNR1–eYPF cells were seeded in 96 multiwell plates, left untreated (control), treated overnight with the
Gi/o inhibitor PTX, 2 h with the Gq/11 inhibitor YM254890, or a combination of both and subsequently loaded with FURA-2 AM. Cells were
challenged with increasing concentrations of agonist, and calcium mobilization was measured as changes in the l340/l380 ratio using a
FLEX-station. Pooled data of three individual experiments is shown. MDCK, Madin–Darby Canine Kidney; eYFP, enhanced yellow fluorescent
protein; SUCNR1, succinate receptor. *Significantly different from control (Po0.05).
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P40.05; Figure 6a). In fact, even agonist pre-treatment for
up to 4 h did not affect the rate at which receptor
resensitization occurred (data not shown). Similar to results
of the Fura-2 measurements, pre-treatment of SUCNR1 cells
with succinate for 15min followed by 5min of stimulation
with 200 mmol/l fresh succinate resulted in decreased levels of
phosphorylated ERK1/2 to 24.6±7.1% compared with the
control cells that had not been subjected to succinate
pre-treatment (Figure 6b). Pre-treatment as above followed
by resensitization for 15min at 371C and subsequent
stimulation with succinate for 5min reversed the desensitiza-
tion effect to a large extent (72.6±8.3% compared with
control) (Figure 6b), indicating that also SUCNR1-induced
ERK1/2 phosphorylation is subject to desensitization and
resensitization.
To further explore the potential internalization of
SUCNR1–eYFP in response to succinate, we performed cell-
surface biotinylation experiments.9–11 Immunoblot analysis
revealed that the cell-surface (biotinylated) fraction of the
mature 90–100 kDa form of SUCNR1–eYFP was not reduced
by treatment with 200 mmol/l succinate for 1 h at 371C
(Figure 6c). This demonstrates that, despite desensitization,
SUCNR1 is resistant to agonist-induced internalization. In
line with this, CLSM analysis of SUCNR1–eYFP cells treated
as above showed no different subcellular localization
compared with untreated control cells (Figure 6d). These
observations indicate that SUCNR1 undergoes rapid desen-
sitization and resensitization, and that the receptor is not
subject to agonist-mediated internalization in polarized
MDCK cells.
Signaling of SUCNR1 in the CD of diabetic mice
As SUCNR1-mediated pERK1/2 signaling may be involved in
the onset of hypertension in diabetes, we assessed whether
signaling events that occur in our polarized cell model can be
extrapolated to the in vivo situation. For this, wild-type
(SUCNRþ /þ ) and SUCNR1 knock-out (SUCRN/)
mice were made diabetic using streptozotocin, whereas
control animals were left untreated. As shown in Figure 7a
and b, only very few cells in the CCD stained positive for
pERK1/2 of wild-type and SUCNR1/ non-diabetic
control mice. In contrast, the amount of pERK1/2-positive
CCD cells in diabetic animals is significantly (Po0.05)
increased compared with non-diabetic animals. As no
pERK1/2 was found in the CCD of diabetic SUCNR/
mice (Figure 7d), the observed increase in pERK1/2 levels in
the CCD of diabetic mice is likely the consequence of
SUCNR1 activation.
DISCUSSION
SUCNR1 is expressed in the luminal membrane of the cortical
thick ascending limb and principal cells of the collecting duct
Northern blot analysis revealed that the kidney is a major site
of expression of the succinate receptor SUCNR1.2 In
addition, analysis of SUCNR1 mRNA expression in different
nephron segments indicated SUCNR1 expression in the
proximal tubule, distal nephron, and JGA.2 Indeed, using
SUCNR1-specific antibodies, Toma et al.4 showed SUCNR1
expression in endothelial cells of the afferent arteriole and in
the glomerulus, where it appeared to regulate renin release
following detection of blood succinate levels. Our data
confirm SUCNR1 expression in the glomerular vasculature
with antibody H-80, likely representing endothelial cells of
the glomerular capillaries and the afferent arterioles. Using
two different antibodies, however, we also observed SUCNR1
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Figure 5 |Activation of SUCNR1 triggers the release of
arachidonic acid and the production of prostaglandins.
(a) Measurement of arichadonic acid release: Untransfected
control cells, MDCK–SUCNR1–eYFP cells were seeded in 24 MW
plates, starved and loaded with[3H]Arachidonic acid (AA).
Subsequently, cells were treated with 200mmol/l succinate (Suc),
100mmol/l ATP or 1 mmol/l ionomycin (Iono) for 15min at 371C.
Subsequently, released [3H]AA was measured by counting the
supernatant in a scintillation counter. Cells were lysed and total
lysates were counted to determine total [3H]AA incorporation into
the cells. The graph shows the percentage of [3H]AA that was
released. Bars indicated with an asterisk are significantly different
from the untreated controls (Po0.05; n¼ 3). (b) Production and
release of prostaglandins: MDCK–SUCNR1–eYFP cells were seeded
on filters and grown to confluence. Subsequently, cells were left
untreated (control) or treated with 200 mmol/l succinate or
100mmol/l ATP for 6 h at 371C. Subsequently, the apical (white
bars) and basolateral (black bars) culture medium was removed
from the cells and analyzed for levels of prostaglandin E2,
prostacyclin I2, and/or their metabolites. Asterisks indicate
significantly (Po0.05; n¼ 3) increased levels compared with
their respective controls. MDCK, Madin–Darby Canine Kidney;
eYFP, enhanced yellow fluorescent protein; SUCNR1, succinate
receptor.
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expression in the luminal membrane of tubular cells of the
cTAL, including macula densa cells (Figures 1 and 2), of
which the latter were located in close proximity to the renin-
producing JGA cells, and in CCD and IMCD principal cells.
In the course of our study, Vargas et al.12 also reported
SUCNR1 expression and signaling in the MD, as confirmed
by co-staining with the MD marker nNOS. The possible
implications of the localization and signaling of the SUCNR1
in cTAL, MD and CD cells is given below.
SUCNR1 signals in response to physiological levels of
succinate
Similar to its localization in renal MD, cTAL and CD
principal cells (Figures 1 and 2, Figures S1 and S2), epitope-
tagged SUCNR1 was expressed in the apical membrane of
MDCK cells (Figure 3b), suggesting that these cells represent
a good model for SUCNR1 localization and regulation in
renal tubular cells. Our data reveal that stimulation of
SUCNR1 in polarized cells induces the same signaling
cascade as found in non-polarized cells, as succinate
increased intracellular calcium levels through the Gq and
the Gi pathway and induced ERK1/2 phosphorylation.
2
Moreover, activation of the SUCNR1 induces the production
and release of PGE2 as observed in vivo.4 Our
MDCK–SUCNR1 cells, however, also secrete PGI2, which is
only released on the apical side (Figure 5). Whether the latter
also occurs in vivo and what physiological effect this may lead
to remains to be established.
The EC50 value for succinate-induced Ca2þ mobiliza-
tion in MDCK cells (23.1±12.8 mmol/l) is of the same
magnitude as described for non-polarized cells by He et al.
(28–68 mmol/l)2 and Toma et al. (69 mmol/l).4 Succinate
excretion via urine in healthy individuals ranges between
2–12mg/day,13 which, based on a daily urinary output of
1.5 l, corresponds to a urinary succinate concentration
between 11 and 67 mmol/l. This indicates that the urinary
succinate levels in healthy individuals are in the physiological
range to activate the tubular SUCNR1.
SUCNR1 undergoes rapid de- and resensitization at the apical
plasma membrane
Interestingly, in our MDCK cells, the SUCNR1 undergoes
desensitization following succinate binding, but is resensi-
tized to control levels very quickly following removal of
succinate (Figure 6). In line with this, the agonists-occupied
SUCNR1 is not degraded (Figure 6c), and cell-surface
biotinylation and immunocytochemistry reveal a similar
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Figure 6 |Desensitization and resensitization of the SUCNR1.
(a) Calcium measurements: MDCK–SUCNR1–eYFP cells were
seeded in 96 MW plates and were left untreated (’), pre-treated
with 200mmol/l succinate (Suc) for 15min (m), followed by
ligand removal and resensitization for 15min (.). Cells were
then challenged with increasing concentrations of agonist and
calcium mobilization was measured and analyzed as described
in the legend to Figure 4. Pooled data of three independent
experiments are shown. (b) ERK1/2 phosphorylation:
MDCK–SUCNR1–eYFP cells were pre-treated with succinate as
above, and subsequently challenged for 5min with 200mmol/l
Suc. Cells were then placed on ice, washed twice with ice-cold
PBS-CM, lysed in sample buffer, and analyzed for phosphorylated
(P) or total ERK1/2 levels by immunoblotting as described in
the legend to Figure 4. (n¼ 3). (c) Plasma membrane localization
of the SUCNR1: MDCK–SUCNR1–eYFP cells were seeded on filters
and grown to confluence. Subsequently, cells were left untreated
(control) or treated with 200 mmol/l succinate for 1 h at 371C.
Cells were rapidly cooled on ice, subjected to apical cell-surface
biotinylation and samples were analyzed by SDS-PAGE followed
by immunoblotting using anti-GFP antibodies. A representative
blot is shown. Immunoblot signals for the cell-surface fraction
of succinate-treated and untreated control cells were quantified
using densitometry and were found to be not significantly
different. (P40.05; n¼ 3) TL; Total lysates, Biot.; biotinylated
cell-surface fraction. (d) Subcellular localization of the SUCNR1:
MDCK–SUCNR1–eYFP cells were grown and pre-treated as
described under c. Subsequently, cells were fixed and analyzed
by CLSM. Shown are representative XY scans (n¼ 4) and a
corresponding cross-section. MDCK, Madin–Darby Canine Kidney;
eYFP, enhanced yellow fluorescent protein; SUCNR1, succinate
receptor.
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membrane localization of the SUCNR1 in untreated control
and succinate-treated cells (Figure 6c and d). Assuming our
MDCK cells mimic SUCNR1 regulation in the cTAL cells, the
vesicles containing some SUCNR1 in MD cells (Figure 2)
may represent recycling vesicles, continuously recycling their
endocytosed proteins to the plasma membrane.
Our data are in contrast to those of He et al.2 who
reported succinate-induced internalization of the SUCNR1 in
HEK293 cells. One possibility is that the SUCNR1 is
regulated differently in non-polarized (HEK293) cells as
compared with polarized cells. On the other hand, however,
the study of He et al.2 lacks important controls to
substantiate their conclusion: Fluorescence microscopy is
less appropriate to determine plasma membrane expression
levels compared with cell-surface biotinylation assays. More-
over, the intracellular expression of the SUCNR1 in cells
without succinate stimulation and plasma membrane
SUCNR1 localization after succinate stimulation were not
determined. It remains to be established whether the
SUCNR1 is internalized in endothelial cells and whether
the regulation of the SUCNR1 in MDCK cells mimics that in
the polarized cTAL/MD/CD cells in vivo.
Putative role of the SUCNR1 in the renal tubule
Succinate is freely filtered in the glomerulus but is normally
reabsorbed in the proximal tubules, mainly via sodium-
dicarboxylate co-transporters.14 As such, SUCNR1-expres-
sing cells of the cTAL, MD, and CCD will only sense succinate
that fails to be reabsorbed in proximal tubules, or that is
excreted by or beyond proximal tubule cells. As indicated
above, however, succinate is found in the urine of healthy
individuals at levels that will stimulate the SUCNR1.13 As
such, the newly-identified localization of SUCNR1 in the
luminal membrane of MD, cTAL, and CD principal cells may
suggest several physiological functions for tubular SUCNR1.
As shown here and as recently described (Figure 1 and12),
the succinate-induced release of PGE2 likely signals to
granular cells, which are in close proximity to the basolateral
side of the MD, to produce and release renin. Considering the
known role of the glomerular endothelial SUCNR1 in
inducing renin expression and release, and the proximal
tubular reabsorption of succinate, the tubular SUCNR1 may
further increase renin production and release only in
conditions of hyperglycemia and diabetes when filtrated
succinate is in excess of reabsorbed levels.
Besides SUCNR1-mediated release of PGE2 to the
basolateral side, tubular activation of the SUCNR1 in the
cTAL and CD may induce apical release of PGE2/PGI2, as
observed in our MDCK cells (Figure 5b). As reported for
tubular prostaglandins derived from cTAL/DCT and CD,15–17
such luminal prostaglandins may reduce blood pressure and
hypertension by reducing NaCl reabsorption in the cTAL and
diminishing water and/or NaCl reabsorption in the DCT and
collecting duct. Alternatively, these luminal prostaglandins
may trigger the release of RAS components from downstream
tubular cells,18 such as renin from the connecting tubule19,20
or (pro)renin from the collecting duct in diabetes,21 which,
via angiotensin II may stimulate sodium retention in the
collecting duct via the epithelial sodium channel ENaC.
However, as the SUCNR1 and renin are co-expressed in
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Figure 7 | Immunolocalization of pERK1/2 in control and diabetic kidney. (a–d) Representative images of pERK1/2 immunofluorescence
(red) in control non-diabetic SUCNR1þ /þ (a), SUCNR1/ (b), and diabetic SUCNRþ /þ (c), GPR91/ (d) kidneys. (e) Summary of
pERK1/2 in control non-diabetic (C) and diabetic (DM) kidney sections based on the number of pERK1/2-positive distal nephron cells per
field. Error bars represent s.e.m. *Po0.05 DM SUCNR1 GPR91þ /þ vs DM SUCNR1/, #Po0.05 vs DM SUCNR1þ /þ (n¼ 6). Nuclei are
stained blue. Scale bar is 20mmol/l. CCD, cortical collecting duct; SUCNR1, succinate receptor.
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IMCD cells (Figure 1l), SUCNR1 may also directly regulate
expression and release of renin and/or regulate water- and salt
transport in this nephron segment. Moreover, SUCNR1-
mediated stimulation of ERK1/2 phosphorylation in the renal
tubules of diabetic mice, as shown in Figure 7, is also observed
in diabetic nephropathy,22 which, in the light of increased renal
succinate levels found in diabetic animals,4 strongly suggests
the involvement of SUCNR1 in this pathological condition.
Interestingly, previous studies showed that in MD cells,
ERK1/2 phosphorylation was increasing in time following
SUCNR1 stimulation,12 which usually points to the presence
of pERK1/2 in the cytosol, where it can activate numerous
cellular pathways. In contrast, in our MDCK cells, which are
derived from more distal tubular cells, we found a transient
rise in ERK1/2 phosphorylation, which is usually associated
with migration of pERK1/2 to the nucleus and cell
proliferation.23 The physiological impact of this discrepancy
remains to be elucidated.
Besides the disease conditions indicated above, renal and/
or tubular succinate levels may also be increased in other
pathological states: at low oxygen levels, Krebs’ cycle
intermediates are converted to succinate24,25 and, as
described for the ischemic retina, SUCNR1 signaling has a
major role in the re-oxygenation and repair of the retina by
stimulating angiogenesis.26 Hypoxic and ischemic conditions
in the kidney are also prevalent during organ transplantation,
in acute and chronic renal failure, and coincide with
increased urinary succinate levels,25,27,28 suggesting that
tubular SUCNR1 activation may have a similar role in the
kidney. The exact role of the tubular SUCNR1 in renal
physiology and disease, however, remains to be established.
MATERIALS AND METHODS
Expression constructs
cDNA encoding the human SUCNR1 was a kind gift of Dr Hampe
and Dr Schaller (University of Hamburg, Hamburg, Germany).
C-terminal fusions of SUCNR1 with enhanced yellow fluorescent
protein (eYFP) or the c-myc epitope tag were generated as described
in the Supplementary materials and methods.
Cell culture and cell assays
MDCKII cells were maintained as described.29 Cells were transfected
with 2.5mg plasmid DNA using Lipofectamine 2000 (Invitrogen,
Paisley, UK) and individual clones selected and isolated as
described.11 Protein sample preparation and EndoH and PNGaseF
digestion were performed as described.29 Cell-surface biotinylation
experiments, ERK1/2 phosphorylation assays, calcium mobilization
assays, and [3H] Arachidonic acid release assays were carried out as
described in the Supplementary materials and methods. Samples for
prostanoid analysis were prepared as described30 and analyzed as
described in the Supplementary materials and methods.
Immunoblotting and immunocytochemistry
Immunoblotting and immunohistochemistry were performed as
described in the Supplementary materials and methods. Primary
antibodies used were Rabbit-anti- ERK1/2, mouse-anti-phospho-
ERK1/2 (Cell Signalling), rat-anti-E-Cadherin, and rabbit-anti-
calnexin (Sigma, Poole, UK). Secondary antibodies used were
HRP-conjugated donkey-anti-goat (Sigma), goat-anti-rabbit or
goat-anti-mouse antibodies (GE Healthcare, Chalfont St Giles,
UK) and Alexa633-conjugated goat-anti-rat, goat-anti- rabbit, or
Alexa488-coupled goat-anti-rabbit or goat-anti-mouse antibodies
(Molecular Probes, Eugene, OR, USA).
SUCNR1/ mice and induction of diabetes
All experiments were performed under protocols approved by the
Institutional Animal Care and Use Committee at University of
Southern California. Breeding pairs of SUCNR1 /þ mice
(C57BL6 background) were provided by Amgen (Thousand Oaks,
CA, USA) and bred at University of Southern California. In male
SUCNR1/ mice, or their wild-type littermates, diabetes was
induced by daily streptozotocin injection for 4 days as described.12
Immunohistochemistry
Kidney sections were prepared and immunolabeling was performed as
previously described4,12,31 and analyzed as described in the Supple-
mentary materials and methods. Secondary antibodies used were
goat-anti-rabbit, Alexa Fluor488; goat-anti-chicken, Alexa Fluor546;
donkey-anti-goat, Alexa Fluor488 (Molecular Probes, Invitrogen).
Primary antibodies used were rabbit-anti-GPR91(H80), goat-anti-
GPR91(Q15, Santa Cruz, Heidelberg, Germany), rabbit-anti-GPR91
(Millipore, Watford, UK), rabbit anti-GPR91 (Novus Biologicals,
Littleton, CO, USA), chicken-anti-renin (kind gift of Hayo Castrup,
University of Regensburg, Germany), chicken-anti-AQP2, and rabbit-
anti-pERK1/2 antibodies (Cell Signaling, Hitchin, UK).
Immunogold electron microscopy
Ultra thin (70 nmol/l) cryosections from perfusion fixed rat kidney
cortex were prepared and analyzed as described in the Supplemen-
tary materials and methods. Primary antibodies were rabbit-anti-
GPR91(H80) or goat-anti-GPR91(Q15). Primary antibodies were
visualized using goat-anti-rabbit or rabbit-anti-goat antibodies
conjugated to 10 nmol/l colloidal gold particles (BioCell Research
Laboratories, UK).
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